Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
Alnylam is at the new frontier of medicines: "It will have the same impact on the industry as antibodies"
The first RNAi medicines are entering the market, showing pioneer of the drug class Klaus Charissé (Alnylam) that the RNAi revolution is taking hold.
WS Audiology plans to list subsidiary
Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list Hear.com, which handles online sales.
Janssen had better Darzalex sales than expected in Q1
Outside the US, Darzalex sales are going so well that they are close to overtaking US sales for Q1. In total, sales amounted to USD 1.37, from which Genmab receives royalties.
Denmark discusses vaccine swap with other countries
Denmark is currently discussing swapping the Astrazeneca vaccine for other vaccines with multiple countries.
Janssen receives new approval for Darzalex in Canada
Canadian authorities have approved the use of Darzalex, which is Genmab-developed, for treating the rare disease amyloidosis.
Regulatory Affairs Associate - Orifarm 
Senior Manager, Regulatory Affairs CMC, New Markets & Life Cycle Management - Y-mAbs Therapeutics 
Director of Global Marketing - Ascelia Pharma 
Pharmacovigilance Director - Zealand Pharma 
R&D Process Manager - Genmab 
Statistical Programmer, Specialist - Lundbeck 
Project Manager, Unilabs 
System Engineer for novel stem cell devices - Novo Nordisk 
Electronics / HW Engineer for the development of medical devices 
Development Chemist for Drug Product Development - ALK